Cargando…

Bevacizumab and radiotherapy for the treatment of glioblastoma: brothers in arms or unholy alliance?

Glioblastoma (GBM) represents the most frequent primary brain tumor in adults and carries a dismal prognosis despite aggressive, multimodal treatment regimens involving maximal resection, radiochemotherapy, and maintenance chemotherapy. Histologically, GBMs are characterized by a high degree of VEGF...

Descripción completa

Detalles Bibliográficos
Autores principales: Niyazi, Maximilian, Harter, Patrick N., Hattingen, Elke, Rottler, Maya, von Baumgarten, Louisa, Proescholdt, Martin, Belka, Claus, Lauber, Kirsten, Mittelbronn, Michel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4823037/
https://www.ncbi.nlm.nih.gov/pubmed/26575171
http://dx.doi.org/10.18632/oncotarget.6320
_version_ 1782425843875708928
author Niyazi, Maximilian
Harter, Patrick N.
Hattingen, Elke
Rottler, Maya
von Baumgarten, Louisa
Proescholdt, Martin
Belka, Claus
Lauber, Kirsten
Mittelbronn, Michel
author_facet Niyazi, Maximilian
Harter, Patrick N.
Hattingen, Elke
Rottler, Maya
von Baumgarten, Louisa
Proescholdt, Martin
Belka, Claus
Lauber, Kirsten
Mittelbronn, Michel
author_sort Niyazi, Maximilian
collection PubMed
description Glioblastoma (GBM) represents the most frequent primary brain tumor in adults and carries a dismal prognosis despite aggressive, multimodal treatment regimens involving maximal resection, radiochemotherapy, and maintenance chemotherapy. Histologically, GBMs are characterized by a high degree of VEGF-mediated vascular proliferation. In consequence, new targeted anti-angiogenic therapies, such as the monoclonal anti-VEGF-A antibody bevacizumab, have proven effective in attenuating tumor (neo)angiogenesis and were shown to possess therapeutic activity in several phase II trials. However, the role of bevacizumab in the context of multimodal therapy approaches appears to be rather complex. This review will give insights into current concepts, limitations, and controversies regarding the molecular mechanisms and the clinical benefits of bevacizumab treatment in combination with radio(chemo)therapy - particularly in face of the results of recent phase III trials, which failed to demonstrate convincing improvements in overall survival (OS).
format Online
Article
Text
id pubmed-4823037
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-48230372016-05-03 Bevacizumab and radiotherapy for the treatment of glioblastoma: brothers in arms or unholy alliance? Niyazi, Maximilian Harter, Patrick N. Hattingen, Elke Rottler, Maya von Baumgarten, Louisa Proescholdt, Martin Belka, Claus Lauber, Kirsten Mittelbronn, Michel Oncotarget Review Glioblastoma (GBM) represents the most frequent primary brain tumor in adults and carries a dismal prognosis despite aggressive, multimodal treatment regimens involving maximal resection, radiochemotherapy, and maintenance chemotherapy. Histologically, GBMs are characterized by a high degree of VEGF-mediated vascular proliferation. In consequence, new targeted anti-angiogenic therapies, such as the monoclonal anti-VEGF-A antibody bevacizumab, have proven effective in attenuating tumor (neo)angiogenesis and were shown to possess therapeutic activity in several phase II trials. However, the role of bevacizumab in the context of multimodal therapy approaches appears to be rather complex. This review will give insights into current concepts, limitations, and controversies regarding the molecular mechanisms and the clinical benefits of bevacizumab treatment in combination with radio(chemo)therapy - particularly in face of the results of recent phase III trials, which failed to demonstrate convincing improvements in overall survival (OS). Impact Journals LLC 2015-11-13 /pmc/articles/PMC4823037/ /pubmed/26575171 http://dx.doi.org/10.18632/oncotarget.6320 Text en Copyright: © 2016 Niyazi et al. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Review
Niyazi, Maximilian
Harter, Patrick N.
Hattingen, Elke
Rottler, Maya
von Baumgarten, Louisa
Proescholdt, Martin
Belka, Claus
Lauber, Kirsten
Mittelbronn, Michel
Bevacizumab and radiotherapy for the treatment of glioblastoma: brothers in arms or unholy alliance?
title Bevacizumab and radiotherapy for the treatment of glioblastoma: brothers in arms or unholy alliance?
title_full Bevacizumab and radiotherapy for the treatment of glioblastoma: brothers in arms or unholy alliance?
title_fullStr Bevacizumab and radiotherapy for the treatment of glioblastoma: brothers in arms or unholy alliance?
title_full_unstemmed Bevacizumab and radiotherapy for the treatment of glioblastoma: brothers in arms or unholy alliance?
title_short Bevacizumab and radiotherapy for the treatment of glioblastoma: brothers in arms or unholy alliance?
title_sort bevacizumab and radiotherapy for the treatment of glioblastoma: brothers in arms or unholy alliance?
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4823037/
https://www.ncbi.nlm.nih.gov/pubmed/26575171
http://dx.doi.org/10.18632/oncotarget.6320
work_keys_str_mv AT niyazimaximilian bevacizumabandradiotherapyforthetreatmentofglioblastomabrothersinarmsorunholyalliance
AT harterpatrickn bevacizumabandradiotherapyforthetreatmentofglioblastomabrothersinarmsorunholyalliance
AT hattingenelke bevacizumabandradiotherapyforthetreatmentofglioblastomabrothersinarmsorunholyalliance
AT rottlermaya bevacizumabandradiotherapyforthetreatmentofglioblastomabrothersinarmsorunholyalliance
AT vonbaumgartenlouisa bevacizumabandradiotherapyforthetreatmentofglioblastomabrothersinarmsorunholyalliance
AT proescholdtmartin bevacizumabandradiotherapyforthetreatmentofglioblastomabrothersinarmsorunholyalliance
AT belkaclaus bevacizumabandradiotherapyforthetreatmentofglioblastomabrothersinarmsorunholyalliance
AT lauberkirsten bevacizumabandradiotherapyforthetreatmentofglioblastomabrothersinarmsorunholyalliance
AT mittelbronnmichel bevacizumabandradiotherapyforthetreatmentofglioblastomabrothersinarmsorunholyalliance